Coping Mechanisms for Financial Toxicity Among Patients With Metastatic Prostate Cancer: A Survey-based Assessment
暂无分享,去创建一个
S. Boorjian | Vidit Sharma | D. Penson | J. Tilburt | P. Schulte | S. Dusetzina | E. Kwon | Daniel D. Joyce | K. Moses | Vidit Sharma
[1] S. Boorjian,et al. Out-of-Pocket Cost Burden Associated With Contemporary Management of Advanced Prostate Cancer Among Commercially Insured Patients , 2022, The Journal of urology.
[2] E. Antonarakis,et al. Evaluation of Medicare Coverage and Estimated Out-of-Pocket Costs for Generic Abiraterone Products , 2022, JAMA network open.
[3] K. Westrich,et al. Predictors of adherence to oral anticancer medications: An analysis of 2010-2018 US nationwide claims , 2022, Journal of managed care & specialty pharmacy.
[4] N. Keating,et al. Many Medicare Beneficiaries Do Not Fill High-Price Specialty Drug Prescriptions. , 2022, Health affairs.
[5] P. Lefebvre,et al. Medication adherence among patients with advanced prostate cancer using oral therapies. , 2021, Future oncology.
[6] R. Shi,et al. The Effect of Payer Status on Survival of Patients With Prostate Cancer , 2021, Cureus.
[7] M. Cooperberg,et al. Patient-Reported Financial Toxicity Associated with Contemporary Treatment for Localized Prostate Cancer. , 2020, The Journal of urology.
[8] T. Skolarus,et al. Adherence and out‐of‐pocket costs among Medicare beneficiaries who are prescribed oral targeted therapies for advanced prostate cancer , 2020, Cancer.
[9] C. Kennedy,et al. Conversations About Financial Issues in Routine Oncology Practices: A Multicenter Study. , 2019, Journal of oncology practice.
[10] N. Keating,et al. Specialty Drug Pricing and Out-of-Pocket Spending on Orally Administered Anticancer Drugs in Medicare Part D, 2010 to 2019. , 2019, JAMA.
[11] Justin P Huynh,et al. Use of Charity Financial Assistance for Novel Oral Anticancer Agents. , 2018, Journal of oncology practice.
[12] D. Goldstein,et al. Trajectories of Injectable Cancer Drug Costs After Launch in the United States. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] L. Gordon,et al. A Systematic Review of Financial Toxicity Among Cancer Survivors: We Can’t Pay the Co-Pay , 2017, The Patient - Patient-Centered Outcomes Research.
[14] Y. Shih,et al. Rising Prices of Targeted Oral Anticancer Medications and Associated Financial Burden on Medicare Beneficiaries. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] A. Jemal,et al. Do cancer survivors change their prescription drug use for financial reasons? Findings from a nationally representative sample in the United States , 2017, Cancer.
[16] L. Zullig,et al. The Role of Patient Financial Assistance Programs in Reducing Costs for Cancer Patients. , 2017, Journal of managed care & specialty pharmacy.
[17] Vinay Prasad,et al. The high price of anticancer drugs: origins, implications, barriers, solutions , 2017, Nature Reviews Clinical Oncology.
[18] P. Newcomb,et al. Financial Insolvency as a Risk Factor for Early Mortality Among Patients With Cancer. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] J. Doshi,et al. Financial toxicity in insured patients with multiple myeloma: a cross-sectional pilot study. , 2015, The Lancet. Haematology.
[20] E. Bruera,et al. Financial Distress and Its Associations With Physical and Emotional Symptoms and Quality of Life Among Advanced Cancer Patients. , 2015, The oncologist.
[21] Thomas J. Smith,et al. Trends in the Cost and Use of Targeted Cancer Therapies for the Privately Insured Nonelderly: 2001 to 2011. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] L. Pusztai,et al. Impact of financial burden of cancer on survivors' quality of life. , 2014, Journal of oncology practice.
[23] Aaron N. Winn,et al. Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] A. Abernethy,et al. Patient-oncologist cost communication, financial distress, and medication adherence. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] A. Abernethy,et al. Full disclosure--out-of-pocket costs as side effects. , 2013, The New England journal of medicine.
[26] C. Bennett,et al. Can Patients Afford to Be Adherent to Expensive Oral Cancer Drugs?: Unintended Consequences of Pharmaceutical Development. , 2013, Journal of oncology practice.
[27] A. Abernethy,et al. Financial toxicity, Part I: a new name for a growing problem. , 2013, Oncology.
[28] E. Taylor,et al. Drug pricing and value in oncology. , 2010, The oncologist.
[29] W. Shrank,et al. Drug company-sponsored patient assistance programs: a viable safety net? , 2009, Health affairs.
[30] L. Casalino,et al. Patient-physician communication about out-of-pocket costs. , 2003, JAMA.